Listed by the USPTO as BERHANE, SELAM
Tech Center 1600 • Art Units: 1642 1643 1649 1675
This examiner grants 59% of resolved cases
Berhane, Selam resolved 93 cases in Tech Center 1600 and Art Unit 1642. The allowance rate was 59.1%, and the median time to allowance was 1322 days. Interview lift was 56.4%, showing a substantial positive association between interviews and allowance outcomes.
The leading companies were Acceleron Pharma Inc., Novartis AG, and Pharmazz Inc. The principal firms were FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, BALLARD SPAHR LLP, and BANNER & WITCOFF, LTD. The moderate allowance rate and lengthy median timeline suggest meaningful prosecution friction. The interview figure makes early preparation for substantive examiner discussions particularly relevant, especially where claim amendments may resolve focused issues.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18258758 | AMYLOID-SPECIFIC ANTIBODIES AND USES THEREOF | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18566564 | METHODS AND COMPOSITIONS FOR LOCALIZATION OF GROWTH FACTORS | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.1% of resolved applications examined by Selam Berhane were allowed (93 resolved cases), compared with 38.5% across Art Unit 1642 over the last five years.
This examiner's interview lift is +56.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Selam Berhane took 1,322 days on average from filing to allowance.
Selam Berhane examines applications in Art Unit 1642 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
